Philips and BioIntelliSense form strategic collaboration to enhance
remote patient monitoring for at-risk patients from the hospital
into the home
July 9, 2020
- Philips integrates the BioIntelliSense FDA-cleared BioSticker™
sensor as part of its remote patient monitoring solutions for
patients outside the hospital
- Multi-parameter sensors aid monitoring across multiple chronic
conditions with medical-grade vital signs for physicians to
remotely track core symptoms, including COVID-19
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced it has formed a strategic collaboration with
BioIntelliSense, a continuous health monitoring and clinical
intelligence company, to integrate its BioSticker™ medical device
into Philips’ remote patient monitoring (RPM) offering to help
monitor at-risk patients from the hospital into the home.
With the addition of multi-parameter sensors, Philips’ solutions
can enhance how clinicians monitor patient populations living with
chronic conditions – including diabetes, cancer, congestive heart
failure and more - in their homes with passive monitoring of
key vital signs, physiological biometrics and symptomatic events
via a discreet wearable patch for monitoring up to 30 days.
Remote patient monitoring and telehealth-enabled clinical
programs offer care teams a sustainable and scalable way to manage
patient populations with chronic or complex conditions at home, and
plays a key role in supporting care for COVID-19 patients who do
not require hospitalization. By regularly transmitting patient data
that can provide critical insights into a patient’s condition, the
collaboration will empower care teams in the U.S. with a more
holistic patient view and the ability to intervene earlier before
adverse events occur. With single-use sensors and
patient-owned technology supporting remote monitoring, care teams
can also help reduce the need for clinicians and patients to
interact in person.
“With more patients interacting with their doctors from home and
more hospitals developing strategies to virtually engage with their
patients, remote patient monitoring is now, more than ever, an
essential tool,” said Roy Jakobs, Chief Business Leader Connected
Care, member of the Executive Committee at Royal Philips. “Building
on Philips’ global leadership in patient monitoring, which includes
an extensive suite of advanced monitoring solutions, platforms and
sensors, this is the latest example of our capability to allow more
seamless, cloud-based data collection across multiple settings from
the home to the hospital and back into the home. Patient data,
coupled with our clinically differentiated and leading AI-powered
technology, quantifies the data into relevant actionable insights
to help detect deterioration trends and support care interventions
– all while outside the walls of the hospital.”
Wireless, secure data transfer of key vital
signsThe BioSticker is a single-use, FDA-cleared 510k
class II wearable medical device to enable at-home continuous
passive monitoring with minute level data across a broad set of
vital signs, physiological biometrics and symptomatic events (skin
temperature, resting heart rate, resting respiratory rate, body
position, activity levels, cough frequency) on a single device for
thirty-days. Symptoms, including those directly associated with
COVID-19 such as temperature and respiratory rate, can be remotely
monitored in confirmed cases of Coronavirus and also for those
patients not sick enough to be hospitalized, or those suspected of
having COVID-19. In addition to COVID-19, the BioSticker device
will help transform the way clinicians monitor and manage patients
living with chronic conditions from the home.
“Multi-parameter sensors are the natural next phase for remote
monitoring, especially at a time when more patients are engaging
with their physicians from home,” said James Mault, MD, Founder and
Chief Executive Officer of BioIntelliSense. “Clinicians need
medical grade monitoring and algorithmic clinical insights for
COVID-19 exposure, symptoms and management. Accelerated by the
COVID-19 crisis, the practice of medicine has been irreversibly
enlightened as to the safety and efficacy of virtual care. Philips
is a demonstrated leader in remote patient monitoring, and we look
forward to BioIntelliSense’s technology playing an integral
role in simplifying and enhancing outcomes for patients and their
doctors.”
Healthcare Highways first to leverage BioSticker as a
part of Philips’ RPM solutions Healthcare Highways, a
leading provider of health plans, high performance provider
networks, pharmacy benefit management, population health
management, and benefit plan administration, is the first to
leverage the BioSticker sensor as a part of Philips’ RPM program in
the U.S. Out of the seven programs that will be deployed with
Healthcare Highways, one will focus specifically on monitoring
patients with COVID-19. The remaining six will focus on conditions
across the acuity spectrum, including patients with congestive
heart failure, hypertension, diabetes, total joint replacement,
cancer and asthma. The program will help Healthcare Highways
improve insights to patient health status across its provider
network.
“Healthcare Highways was built on the idea of delivering
measurable value and access to quality care to our members. We work
in partnership with our providers to innovate on the care model,
and look at Remote Patient Monitoring as the next frontier of how
providers will connect with patients,” said Creagh Milford, DO,
MPH, Chief Medical Officer of Healthcare Highways and Chief
Executive Officer of HighCare Health. “COVID-19 has underscored the
need for proactive care management. Resources are strained and by
integrating an RPM program with biosensor technology, we’ll be able
to drive further value for our unique member base, providers and
employers to establish a new way of care delivery.”
Philips’ remote patient monitoring offerings are part of the
company’s broader Population Health Management portfolio, which
provides a comprehensive and proactive healthcare delivery strategy
to connect clinicians, providers and patients for ongoing care. By
combining technology and data-driven population management with
clinical expertise and a proven programmatic approach, Philips
supports the delivery of telehealth services for programs in and
out of the hospital to provide connected, patient-centered care
across the health continuum.
For further information, please contact:
Kathy O’ReillyPhilips Global Press OfficeTel: +1 978 221
8919Email: Kathy.oreilly@philips.comTwitter: @kathyoreilly
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2019
sales of EUR 19.5 billion and employs approximately 81,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
About BioIntelliSense BioIntelliSense is
ushering in a new era of continuous health monitoring and clinical
intelligence for Remote Patient Monitoring (RPM). Its medical-grade
Data-as-a-Service (DaaS) platform seamlessly captures
minute-to-minute vital signs, physiological biometrics and
symptomatic events through an effortless patient experience. For
more information on how BioIntelliSense is redefining remote
patient monitoring through medical-grade and cost-effective data
services, please visit our website at BioIntelliSense.com.
- BioIntelliSense_Sticker
- Crossword_BO6A1610
- BioIntelliSense_Sticker w Hub
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (EU:PHIA)
Historical Stock Chart
From Apr 2023 to Apr 2024